BAAM
EGRX

Baker Avenue Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Baker Avenue Asset Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15
Closed -$426 – 1786
2023
Q1 		$426 Buy
+15
New +$445 ﹤0.01% 1501

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Baker Avenue Asset Management's EGRX Position: Q2 2023 in Review

Baker Avenue Asset Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2023, closing a stake of 15 shares — an estimated $426 sold.

Baker Avenue Asset Management first reported a position in EGRX in Q1 2023 and held it in 1 quarter. The position peaked at $426 in Q1 2023. 126 funds tracked by Wall St. Rank hold EGRX as of Q2 2023.

  • Baker Avenue Asset Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Baker Avenue Asset Management sold 15 Eagle Pharmaceuticals, Inc. shares in Q2 2023, an estimated $426.
  • Baker Avenue Asset Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2023 and held it in 1 quarter.
  • Baker Avenue Asset Management's Eagle Pharmaceuticals, Inc. position peaked at $426 in Q1 2023.
  • 126 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2023.

Based on Baker Avenue Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.